{"id":"W4385782360","doi":"10.1016/j.jtho.2023.08.010","title":"Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Ceritinib; Internal medicine; Hazard ratio; Clinical endpoint; ALK inhibitor; Confidence interval; Adverse effect; Oncology; Gastroenterology; Randomized controlled trial; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065046,0.0001458583,0.0005416172,0.0004276168,0.00004233209,0.000008334276,0.00008262209,0.000114297,0.0000519194],"category_scores_gemma":[0.0008626056,0.0001050046,0.0002022293,0.0004592916,0.0000897138,0.00009965925,0.00002811556,0.0003398458,0.00002001405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003627504,"about_ca_system_score_gemma":0.001052674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001323612,"about_ca_topic_score_gemma":0.0000194887,"domain_scores_codex":[0.9980898,0.0002570005,0.0008298396,0.0002003923,0.0003785402,0.000244462],"domain_scores_gemma":[0.9980581,0.0005806326,0.0006770108,0.0001766541,0.0002561319,0.0002514715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7527484,0.003361139,0.000410455,0.00005383914,0.0002778093,0.002908046,0.001468454,0.00002668929,0.0004172985,0.000011583,0.002967746,0.2353485],"study_design_scores_gemma":[0.7281039,0.1396414,0.06729313,0.004278282,0.003980848,0.0002347355,0.001963178,0.0003146712,0.008914949,0.0004914619,0.04432395,0.0004595085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855985,0.0002244752,0.00000813355,0.006596902,0.001699124,0.0007962623,0.0001034533,0.00001841189,0.004954743],"genre_scores_gemma":[0.9980113,0.00007260873,0.0005546822,0.0001836469,0.0005725571,0.00005361377,0.00005472758,0.00002053392,0.0004763425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.234889,"threshold_uncertainty_score":0.4281964,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04549059461048759,"score_gpt":0.5245308825252416,"score_spread":0.479040287914754,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}